The recent unveiling of Sylvee, a revolutionary wearable device by US-based start-up Samay, has brought forth remarkable results. This cutting-edge device utilizes artificial intelligence (AI) to aid in the management of chronic obstructive pulmonary disease (COPD). Diverging from conventional diagnostic and monitoring techniques, Sylvee incessantly assesses multiple respiratory functions and seamlessly delivers real-time data via its integration with a mobile app and research portal.
Sylvee integrates advanced technology that merges lung physiology, IoT sensors, signal processing, and AI/ML algorithms. Through the acquisition of pulmonary function data, including early COPD diagnostic biomarkers and exacerbation predictors, Sylvee transforms COPD management and equips patients and healthcare professionals with significant knowledge.
The market for wearable devices has experienced significant expansion, particularly in response to the Covid-19 pandemic. Based on GlobalData analysis, it is anticipated that the market will achieve a value of $156 billion by 2024, while the remote monitoring device market is estimated to be valued at $760 million by 2030.
In collaboration with the Pulmonary, Critical Care & Sleep Disorders Institute of South Florida (PCSI), a study was conducted that involved 110 participants comprising individuals with COPD, asthma, and healthy individuals. The study revealed that Sylvee exhibited exceptional precision in diagnosing COPD, with a success rate of 90%. Furthermore, the device accurately identified the effectiveness of medication during pre-bronchodilation and post-bronchodilation pulmonary function tests (PFTs).
The measurement of air trapping, a biomarker indicating the severity of lung disease, is a crucial aspect of COPD management. has demonstrated an impressive accuracy rate of 83% in detecting air trapping by comparing the differences in residual volume (RV) and total lung capacity (TLC) when compared to traditional PFTs conducted in hospital settings.
Sylvee endeavors to tackle the challenge of preventing adverse outcomes for patients with chronic lung conditions by providing timely data and alerts, enabling healthcare providers to intervene at the earliest signs of deterioration. The early detection and treatment of exacerbations are crucial in achieving this goal.
Sylvee’s potential to revolutionize COPD management is indisputable as it evolves. Sylvee’s unique approach to personalized care, which combines AI, wearable technology, and remote monitoring capabilities, empowers patients to take an active role in their health, resulting in improved outcomes for those living with COPD.
Q: What is Sylvee?
It is an AI-assisted wearable device developedstart-up Samay. It continuously measures various respiratory functions and provides real-time data through its integration with a mobile app and research portal.
Q: How accurate is Sylvee in diagnosing COPD?
Sylvee demonstrated a diagnostic accuracy rate of 90% in diagnosing COPD.
Q: What is the significance of air trapping in COPD?
Air trapping is a measurable biomarker of COPD, indicating lung disease severity. It occurs when air does not leave the lung, leading to changes in lung resonance.
Q: How does Sylvee detect air trapping?
It detects air trappingcomparing differences in residual volume (RV) and total lung capacity (TLC), providing an accuracy rate of 83% compared to traditional pulmonary function tests (PFTs) conducted in hospital settings.
Q: How can Sylvee improve COPD management?
It enhances COPD management and patient outcomes by offering real-time data and alerts, enabling timely detection and intervention in exacerbations.